Pfizer CentreOne vs Piramal Pharma Solutions: CDMO Comparison
How does Pfizer CentreOne compare to Piramal Pharma Solutions for Biologics manufacturing?
Side-by-side comparison of Pfizer CentreOne and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Pfizer CentreOne has materially broader EMA GMP coverage (14 active certificates vs 1) — stronger EU footprint.
- Piramal Pharma Solutions has stronger MHRA / UK coverage (12 compliant certificates vs 3).
- Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (366 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Pfizer CentreOne and Piramal Pharma Solutions qualify as Biologics manufacturers; Pfizer CentreOne carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both Pfizer CentreOne and Piramal Pharma Solutions qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: Pfizer CentreOne vs Piramal Pharma Solutions
How does Pfizer CentreOne compare to Piramal Pharma Solutions for Biologics manufacturing?
On CDMO Signal's composite Signal Score, Pfizer CentreOne is 92/100 and Piramal Pharma Solutions is 84/100; Pfizer CentreOne has 4 FDA inspections on record vs 5 for Piramal Pharma Solutions; European coverage is 17 active EMA+MHRA certificates for Pfizer CentreOne vs 13 for Piramal Pharma Solutions. Both are tracked in the CDMO Signal directory as Biologics CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Pfizer CentreOne or Piramal Pharma Solutions?
Both Pfizer CentreOne and Piramal Pharma Solutions maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Pfizer CentreOne has 4 FDA inspections on record; Piramal Pharma Solutions has 5.
How do Pfizer CentreOne and Piramal Pharma Solutions compare on European GMP coverage?
Pfizer CentreOne holds 14 active EMA GMP certificates and 3 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 12 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Pfizer CentreOne or Piramal Pharma Solutions?
Pfizer CentreOne is matched to 366 ClinicalTrials.gov records as a manufacturing partner; Piramal Pharma Solutions is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Biologics manufacturing — Pfizer CentreOne or Piramal Pharma Solutions?
Both Pfizer CentreOne and Piramal Pharma Solutions are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →